Capecitabine in Combination With Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer, a Phase II Trial

Trial Profile

Capecitabine in Combination With Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer, a Phase II Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Bendamustine (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms MBC-6
  • Most Recent Events

    • 22 Dec 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.
    • 22 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2017.
    • 11 Oct 2016 Results assessing safety parameters presented at the 41st European Society for Medical Oncology Congress (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top